Somatostatin analogues in functioning gastroenteropancreatic neuroendocrine tumours: literature review, clinical recommendations and schedules

References

• Moertel CG. Karnofsky memorial lecture. An odyssey in the land of small tumors. J Clin Oncol. 1987;5:1502–1522.
   PubMedGoogle Scholar
• Reubi JC, Laissue J, Waser B, et al. Expression of somatostatin receptors in normal, inflamed, and neoplastic human gastrointestinal tissues. Ann N Y Acad Sci. 1994;733:122–137.
   PubMed Web of Science ®Google Scholar
• Oberg KE, Reubi JC, Kwekkeboom DJ, et al. Role of somatostatins in gastroenteropancreatic neuroendocrine tumor development and therapy. Gastroenterology. 2010;139:742–753.
   PubMed Web of Science ®Google Scholar
• Corleto VD, Nasoni S, Panzuto F, et al. Somatostatin receptor subtypes: basic pharmacology and tissue distribution. Dig Liver Dis. 2004;36:S816.
   PubMedGoogle Scholar
• Patel YC. Somatostatin and its receptor family. Front Neuroendocrinol. 1999;20:157–198.
   PubMed Web of Science ®Google Scholar
• Grozinsky-Glasberg S, Shimon I, Korbonits M, et al. Somatostatin analogues in the control of neuroendocrine tumours: efficacy and mechanisms. Endocr Relat Cancer. 2008;15:701–720.
   PubMed Web of Science ®Google Scholar
• Balaban CD, Severs WB. Cytotoxic effects of somatostatin in the cerebellum. Ann N Y Acad Sci. 1992;656:802–810.
   PubMed Web of Science ®Google Scholar
• Bousquet C, Puente E, Buscail L, et al. Antiproliferative effect of somatostatin and analogs. Chemotherapy. 2001;47:30–39.
   PubMed Web of Science ®Google Scholar
• Wulbrand U, Feldman M, Pfestroff A, et al. A novel somatostatin conjugate with a high affinity to all five somatostatin receptor subtypes. Cancer. 2002;94:1293–1297.
   PubMed Web of Science ®Google Scholar
• Ferrante E, Pellegrini C, Bondioni S, et al. Octreotide promotes apoptosis in human somatotroph tumor cells by activating somatostatin receptor type 2. Endocr Relat Cancer. 2006;13:955–962.
   PubMed Web of Science ®Google Scholar
• Pyronnet S, Bousquet C, Najib S, et al. Antitumor effects of somatostatin. Mol Cell Endocrinol. 2008;286:230–237.
   PubMed Web of Science ®Google Scholar
• Bauer W, Briner U, Doepfner W, et al. SMS 201–995: a very potent and selective octapeptide analogue of somatostatin with prolonged action. Life Sci. 1982;31:1133–1140.
   PubMed Web of Science ®Google Scholar
• Sassolas G, Khalfallah Y, Chayvialle JA, et al. Effects of the somatostatin analog BIM 23014 on the secretion of growth hormone, thyrotropin, and digestive peptides in normal men. J Clin Endocrinol Metab. 1989;68:239–246.
   PubMed Web of Science ®Google Scholar
• Rubin J, Ajani J, Schirmer W, et al. Octreotide acetate long-acting formulation versus open-label subcutaneous octreotide acetate in malignant carcinoid syndrome. J Clin Oncol. 1999;17:600–606.
   PubMed Web of Science ®Google Scholar
• Caron P, Beckers A, Cullen DR, et al. Efficacy of the new long-acting formulation of lanreotide (lanreotide Autogel) in the management of acromegaly. J Clin Endocrinol Metab. 2002;87:99–104.
   PubMed Web of Science ®Google Scholar
• Modlin IM, Pavel M, Kidd M, et al. Review article: somatostatin analogues in the treatment of gastroenteropancreatic neuroendocrine (carcinoid) tumours. Aliment Pharmacol Ther. 2010;31:169–188.
   PubMed Web of Science ®Google Scholar
• Janson ET, Oberg K. Long-term management of the carcinoid syndrome. Treatment with octreotide alone and in combination with alpha-interferon. Acta Oncol. 1993;32:225–229.
   PubMed Web of Science ®Google Scholar
• Toumpanakis C, Garland J, Marelli L, et al. Long-term results of patients with malignant carcinoid syndrome receiving octreotide LAR. Aliment Pharmacol Ther. 2009;30:733–740.
   PubMed Web of Science ®Google Scholar
• Khan MS, El-Khouly F, Davies P, et al. Long-term results of treatment of malignant carcinoid syndrome with prolonged release Lanreotide (Somatuline Autogel). Aliment Pharmacol Ther. 2011;34:235–242.
   PubMed Web of Science ®Google Scholar
• Attanasio R, Mainolfi A, Grimaldi F, et al. Somatostatin analogs and gallstones: a retrospective survey on a large series of acromegalic patients. J Endocrinol Invest. 2008;31:704–710.
   PubMed Web of Science ®Google Scholar
• Fatti LM, Scacchi M, Lavezzi E, et al. Effects of treatment with somatostatin analogues on QT interval duration in acromegalic patients. Clin Endocrinol (Oxf). 2006;65:626–630.
   PubMed Web of Science ®Google Scholar
• Lamberts SW, van der Lely AJ, Hofland LJ. New somatostatin analogs: will they fulfil old promises? Eur J Endocrinol. 2002;146:701–705.
   PubMed Web of Science ®Google Scholar
• Oberg K, Ferone D, Kaltsas G, et al. ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: biotherapy. Neuroendocrinology. 2009;90:209–213.
   PubMed Web of Science ®Google Scholar
• Oberg K, Kvols L, Caplin M, et al. Consensus report on the use of somatostatin analogs for the management of neuroendocrine tumors of the gastroenteropancreatic system. Ann Oncol. 2004;15:966–973.
   PubMed Web of Science ®Google Scholar
• O’Toole D, Ducreux M, Bommelaer G, et al. Treatment of carcinoid syndrome: a prospective crossover evaluation of lanreotide versus octreotide in terms of efficacy, patient acceptability, and tolerance. Cancer. 2000;88:770–776.
   PubMed Web of Science ®Google Scholar
• Raderer M, Kurtaran A, Scheithauer W, et al. Different response to the long-acting somatostatin analogues lanreotide and octreotide in a patient with a malignant carcinoid. Oncology. 2001;60:141–145.
   PubMed Web of Science ®Google Scholar
• Rinke A, Müller HH, Schade-Brittinger C, et al. PROMID Study Group. Placebo controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group. J Clin Oncol. 2009;27:4656–4663.
   PubMed Web of Science ®Google Scholar
• Caplin ME, Pavel M, Ćwikła JB, et al. Lanreotide in metastatic enteropancreatic neuroendocrine tumors. N Engl J Med. 2014;371:224–233.
   PubMed Web of Science ®Google Scholar
• Shebani KO, Souba WW, Finkelstein DM, et al. Prognosis and survival in patients with gastrointestinal tract carcinoid tumors. Ann Surg. 1999;229:815–821.
   PubMed Web of Science ®Google Scholar
• Atwell TD, Charboneau JW, Que FG, et al. Treatment of neuroendocrine cancer metastatic to the liver: the role of ablative techniques. Cardiovasc Intervent Radiol. 2005;28:409–421.
   PubMed Web of Science ®Google Scholar
• Kvols LK, Moertel CG, O’Connell MJ, et al. Treatment of the malignant carcinoid syndrome. Evaluation of a long-acting somatostatin analogue. N Engl J Med. 1986;315:663–666.
   PubMed Web of Science ®Google Scholar
• Ruszniewski P, Ducreux M, Chayvialle JA, et al. Treatment of the carcinoid syndrome with the longacting somatostatin analogue lanreotide: a prospective study in 39 patients. Gut. 1996;39:279–283.
   PubMed Web of Science ®Google Scholar
• Ruszniewski P, Ish-Shalom S, Wymenga M, et al. Rapid and sustained relief from the symptoms of carcinoid syndrome: results from an open 6-month study of the 28-day prolonged-release formulation of lanreotide. Neuroendocrinology. 2004;80:244–251.
   PubMed Web of Science ®Google Scholar
• Cusati D, Zhang L, Harmsen WS, et al. Metastatic nonfunctioning pancreatic neuroendocrine carcinoma to liver: surgical treatment and outcomes. J Am Coll Surg. 2012;215:117–124; discussion 124. 5.
   PubMed Web of Science ®Google Scholar
• Jensen RT, Cadiot G, Brandi ML, et al. ENETS Consensus Guidelines for the management of patients with digestive neuroendocrine neoplasms: functional pancreatic endocrine tumor syndromes. Neuroendocrinology 2012;95:98–119.
   PubMed Web of Science ®Google Scholar
• Plöckinger U, Wiedenmann B. Neuroendocrine tumors. Biotherapy. Best Pract Res Clin Endocrinol Metab. 2007;21:145–162.
   PubMed Web of Science ®Google Scholar
• Ramage JK, Ahmed A, Ardill J, et al. UK and Ireland Neuroendocrine Tumour Society. Guidelines for the management of gastroenteropancreatic neuroendocrine (including carcinoid) tumours (NETs). Gut. 2012;61:6–32.
   PubMed Web of Science ®Google Scholar
• Frankton S, Bloom SR. Gastrointestinal endocrine tumours. Glucagonomas. Baillieres Clin Gastroenterol. 1996;10:697–705.
   PubMed Web of Science ®Google Scholar
• Nikou GC, Toubanakis C, Nikolaou P, et al. VIPomas: an update in diagnosis and management in a series of 11 patients. Hepatogastroenterology. 2005;52:1259–1265.
   PubMed Web of Science ®Google Scholar
• Angeletti S, Corleto VD, Schillaci O, et al. Use of the somatostatin analogue octreotide to localise and manage somatostatin-producing tumours. Gut. 1998;42:792–794.
   PubMed Web of Science ®Google Scholar
• Srirajaskanthan R, McStay M, Toumpanakis C, et al. Parathyroid hormone-related peptide-secreting pancreatic neuroendocrine tumours: case series and literature review. Neuroendocrinology. 2009;89:48–55.
   PubMed Web of Science ®Google Scholar
• Toumpanakis C, Caplin ME. Update on the role of somatostatin analogs for the treatment of patients with gastroenteropancreatic neuroendocrine tumors. Semin Oncol. 2013;40:56–68.
   PubMed Web of Science ®Google Scholar
• Appetecchia M, Baldelli R. Somatostatin analogues in the treatment of gastroenteropancreatic neuroendocrine tumours, current aspects and new perspectives. J Exp Clin Cancer Res. 2010;29:19.
   PubMed Web of Science ®Google Scholar
• Strosberg J, Kvols L. Antiproliferative effect of somatostatin analogs in gastroenteropancreatic neuroendocrine tumors. World J Gastroenterol. 2010;16:2963–2970.
   PubMed Web of Science ®Google Scholar
• Tomassetti P, Migliori M, Corinaldesi R, et al. Treatment of gastroenteropancreatic neuroendocrine tumours with octreotide LAR. Aliment Pharmacol Ther. 2000;14:557–560.
   PubMed Web of Science ®Google Scholar
• Eriksson B, Renstrup J, Imam H, et al. High-dose treatment with lanreotide of patients with advanced neuroendocrine gastrointestinal tumors: clinical and biological effects. Ann Oncol. 1997;8:1041–1044.
   PubMed Web of Science ®Google Scholar
• Tomassetti P, Migliori M, Gullo L. Slow-release lanreotide treatment in endocrine gastrointestinal tumors. Am J Gastroenterol. 1998;93:1468–1471.
   PubMed Web of Science ®Google Scholar
• Wymenga AN, Eriksson B, Salmela PI, et al. Efficacy and safety of prolonged-release lanreotide in patients with gastrointestinal neuroendocrine tumors and hormone related symptoms. J Clin Oncol. 1999;17:1111
   PubMed Web of Science ®Google Scholar
• Ricci S, Antonuzzo A, Galli L, et al. Long-acting depot lanreotide in the treatment of patients with advanced neuroendocrine tumors. Am J Clin Oncol. 2000;23:12–15.
   Web of Science ®Google Scholar
• Arnold R, Trautmann ME, Creutzfeldt W, et al. Somatostatin analogue octreotide and inhibition of tumour growth in metastatic endocrine gastroenteropancreatic tumours. Gut. 1996;38:430–438.
   PubMed Web of Science ®Google Scholar
• Saltz L, Trochanowski B, Buckley M, et al. Octreotide as an antineoplastic agent in the treatment of functional and nonfunctional neuroendocrine tumors. Cancer. 1993;72:244–248.
   PubMed Web of Science ®Google Scholar
• di Bartolomeo M, Bajetta E, Buzzoni R, et al. Clinical efficacy of octreotide in the treatment of metastatic neuroendocrine tumors. A study by the Italian Trials in Medical Oncology Group. Cancer. 1996;77:402–408.
   PubMed Web of Science ®Google Scholar
• Ricci S, Antonuzzo A, Galli L, et al. Octreotide acetate long-acting release in patients with metastatic neuroendocrine tumors pretreated with lanreotide. Ann Oncol. 2000;11:1127–1130.
   PubMed Web of Science ®Google Scholar
• Aparicio T, Ducreux M, Baudin E, et al. Antitumour activity of somatostatin analogues in progressive metastatic neuroendocrine tumours. Eur J Cancer. 2001;37:1014–1019.
   PubMed Web of Science ®Google Scholar
• Faiss S, Räth U, Mansmann U, et al. Ultra-high-dose lanreotide treatment in patients with metastatic neuroendocrine gastroenteropancreatic tumors. Digestion. 1999;60:469–476.
   PubMed Web of Science ®Google Scholar
• Faiss S, Pape UF, Böhmig M, et al. International Lanreotide and Interferon Alfa Study Group. Prospective, randomized, multicenter trial on the antiproliferative effect of lanreotide, interferon alfa, and their combination for therapy of metastatic neuroendocrine gastroenteropancreatic tumors—the International Lanreotide and Interferon Alfa Study Group. J Clin Oncol. 2003;21:2689–2696.
   PubMed Web of Science ®Google Scholar
• Ducreux M, Ruszniewski P, Chayvialle JA, et al. The antitumoral effect of the long-acting somatostatin analog lanreotide in neuroendocrine tumors. Am J Gastroenterol. 2000;95:3276–3281.
   PubMed Web of Science ®Google Scholar
• Bianchi A, De Marinis L, Fusco A, et al. The treatment of neuroendocrine tumors with long-acting somatostatin analogs: a single center experience with lanreotide Autogel. J Endocrinol Invest. 2011;34:692–697.
   PubMed Web of Science ®Google Scholar
• Palazzo M, Lombard-Bohas C, Cadiot G, et al. Predictive factors of tumor control in patients with well-differentiated digestive endocrine carcinomas (WDEK) treated with lanreotide. Paper presented at the 19th United European Gastroenterology Week; 2011 Oct 22–26; Stockholm, Sweden.
   Google Scholar
• Massironi S, Conte D, Sciola V, et al. Plasma chromogranin A response to octreotide test: prognostic value for clinical outcome in endocrine digestive tumors. Am J Gastroenterol. 2010;105:2072–2078.
   PubMed Web of Science ®Google Scholar
• Anthony L, Johnson D, Hande K, et al. Somatostatin analogue phase I trials in neuroendocrine neoplasms. 1 trials in neuroendocrine neoplasms. Acta Oncologica. 1993;32:217–223.
   PubMed Web of Science ®Google Scholar
• Ferolla P, Faggiano A, Grimaldi F, et al. Shortened interval of long-acting octreotide administration is effective in patients with well-differentiated neuroendocrine carcinomas in progression on standard doses. J Endocrinol Invest. 2012;35:326–331.
   PubMed Web of Science ®Google Scholar
• Al-Efraij K, Aljama MA, Kennecke HF. Association of dose escalation of octreotide long-acting release on clinical symptoms and tumor markers and response among patients with neuroendocrine tumors. Cancer Med. 2015;4:864–870.
   PubMed Web of Science ®Google Scholar
• Imam H, Eriksson B, Lukinius A, et al. Induction of apoptosis in neuroendocrine tumors of the digestive system during treatment with somatostatin analogs. Acta Oncologica. 1997;36:607–614.
   PubMed Web of Science ®Google Scholar
• Welin SV, Janson ET, Sundin A, et al. High-dose treatment with a long-acting somatostatin analogue in patients with advanced midgut carcinoid tumours. Eur J Endocrinol. 2004;151:107–112.
   PubMed Web of Science ®Google Scholar
• Chadha MK, Lombardo J, Mashtare T, et al. High-dose octreotide acetate for management of gastroenteropancreatic neuroendocrine tumors. Anticancer Res. 2009;29:4127–4130.
   PubMed Web of Science ®Google Scholar
• Broder MS, Beenhouwer D, Strosberg JR, et al. Gastrointestinal neuroendocrine tumors treated with high dose octreotide-LAR: a systematic literature review. World J Gastroenterol. 2015;21:1945–1955.
   PubMed Web of Science ®Google Scholar
• Pavel M, Baudin E, Couvelard A, et al. Barcelona Consensus Conference participants. ENETS Consensus Guidelines for the management of patients with liver and other distant metastases from neuroendocrine neoplasms of foregut, midgut, hindgut, and unknown primary. Neuroendocrinology. 2012;95:157–176.
   PubMed Web of Science ®Google Scholar
• Frank M, Klose KJ, Wied M, et al. Combination therapy with octreotide and alpha-interferon: effect on tumor growth in metastatic endocrine gastroenteropancreatic tumors. Am J Gastroenterol. 1999;94:1381–1387.
   PubMed Web of Science ®Google Scholar
• Kölby L, Persson G, Franzén S, et al. Randomized clinical trial of the effect of interferon alpha on survival in patients with disseminated midgut carcinoid tumours. Br J Surg. 2003;90:687–693.
   PubMed Web of Science ®Google Scholar
• Mirvis E, Mandair D, Garcia-Hernandez J, et al. Role of interferon-alpha in patients with neuroendocrine tumors: a retrospective study. Anticancer Res. 2014;34:6601–6607.
   PubMed Web of Science ®Google Scholar
• Arnold R, Rinke A, Klose KJ, et al. Octreotide versus octreotide plus interferon-alpha in endocrine gastroenteropancreatic tumors: a randomized trial. Clin Gastroenterol Hepatol. 2005;3:761–771.
   PubMed Web of Science ®Google Scholar
• Yao JC, Phan A, Hoff PM, et al. Targeting vascular endothelial growth factor in advanced carcinoid tumor: a random assignment phase II study of depot octreotide with bevacizumab and pegylated interferon alpha-2b. J Clin Oncol. 2008;26:1316–1323.
   PubMed Web of Science ®Google Scholar
• Yao JC, Lombard-Bohas C, Baudin E, et al. Daily oral everolimus activity in patients with metastatic pancreatic neuroendocrine tumors after failure of cytotoxic chemotherapy: a phase II trial. J Clin Oncol. 2010;28:69–76.
   PubMed Web of Science ®Google Scholar
• Pavel ME, Hainsworth JD, Baudin E, et al. RADIANT-2 Study Group. Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study. Lancet. 2011;378:2005–2012.
   PubMed Web of Science ®Google Scholar
• Valle J, Faivre S, Raoul JL, et al. Phase III trial of sunitinib (SU) versus placebo (PBO) for treatment of pancreatic neuroendocrine tumors (NET): impact of somatostatin analogue (SSA) treatment on progression-free survival (PFS). Paper presented at the European Society for Medical Oncology; 2010 Oct 8–12; Milan, Italy.
   Google Scholar
• Pusceddu S, de Braud F, Concas L, et al. Rationale and protocol of the MetNET-1 trial, a prospective, single center, phase II study to evaluate the activity and safety of everolimus in combination with octreotide LAR and metformin in patients with advanced pancreatic neuroendocrine tumors. Tumori. 2014;100:286e–289e.
   PubMed Web of Science ®Google Scholar
• Kvols LK, Oberg KE, O'Dorisio TM, et al. Pasireotide (SOM230) shows efficacy and tolerability in the treatment of patients with advanced neuroendocrine tumors refractory or resistant to octreotide LAR: results from a phase II study. Endocr Relat Cancer. 2012;19:657–666.
   PubMed Web of Science ®Google Scholar
• Wolin EM, Hu K, Hughes G, et al. Safety, tolerability, pharmacokinetics, and pharmacodynamics of a long-acting release (LAR) formulation of pasireotide (SOM230) in patients with gastroenteropancreatic neuroendocrine tumors: results from a randomized, multicenter, open-label, phase I study. Cancer Chemother Pharmacol. 2013;72:387–395.
   PubMed Web of Science ®Google Scholar
• Cives M, Kunz PL, Morse B, et al. Phase II clinical trial of pasireotide long-acting repeatable in patients with metastatic neuroendocrine tumors. Endocr Relat Cancer. 2015;22:1–9.
   PubMed Web of Science ®Google Scholar
• Srirajaskanthan R, Watkins J, Marelli L, et al. Expression of somatostatin and dopamine 2 receptors in neuroendocrine tumours and the potential role for new biotherapies. Neuroendocrinology. 2009;89:308–314.
   PubMed Web of Science ®Google Scholar